Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The organic cation transporters involved in the renal clearance of paliperidone are a group of membrane proteins that facilitate the active secretion of the drug from the blood into the urine. This system primarily consists of the organic cation transporter 2 (OCT2/SLC22A2), located on the basolateral membrane of renal proximal tubule cells, and the multidrug and toxin extrusion proteins 1 and 2-K (MATE1/SLC47A1 and MATE2-K/SLC47A2), located on the apical membrane [4, 12, 16]. Paliperidone, an atypical antipsychotic, is significantly dependent on renal elimination, with approximately 59% of a dose excreted unchanged in the urine [1, 3]. The coordinated action of these transporters ensures the efficient removal of paliperidone, which exists as a cation at physiological pH [2]. Although clinical studies with inhibitors like trimethoprim have shown that these transporters may not be the sole determinants of paliperidone's pharmacokinetics, they are critical components of its renal disposition [2, 6]. In patients with renal impairment, the reduced activity of these transporters leads to decreased clearance and increased systemic exposure, necessitating dose adjustments to avoid toxicity [3, 8]. Furthermore, interactions with other drugs that inhibit or compete for these transporters can potentially alter paliperidone levels, although such effects are often secondary to the influence of P-glycoprotein (P-gp), which also contributes to its renal secretion [7, 19]. Understanding the role of these transporters is vital for clinicians to manage the risk of dose-dependent adverse effects such as extrapyramidal symptoms and prolactin elevation [3, 10]. Overall, the OCT/MATE system is a key determinant of the safety and efficacy profile of paliperidone in diverse patient populations [15, 17].
Active tubular secretion of organic cations via basolateral uptake and apical efflux
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Organic cation transporter 2 (OCT2), Multidrug and toxin extrusion protein 1 (MATE1), and Multidrug and toxin extrusion protein 2-K (MATE2-K) (OCTs/MATEs).